Thompson Rahsaan 4

What Happened

• Thompson Rahsaan, Chief Legal & Compliance at Zevra Therapeutics, sold 1,794 shares on 2026-05-11.
• The shares were disposed at $11.30 per share for a total of roughly $20,272. The Form 4 lists the transaction as a sale (code S).

Key Details

• Transaction date: 2026-05-11; Filing date: 2026-05-13 (filed within two business days, appears timely).
• Price per share: $11.30; Total proceeds: ~$20,272.
• Shares owned after the transaction: not disclosed in the provided filing.
• Footnote: sale was made under a pre-established 10b5‑1 trading plan adopted 2026-01-08 (per Form 4 footnote).
• Transaction type: open-market or private sale as reported on the Form 4.

Context

• This was a straight sale of shares. Sales under 10b5‑1 plans are typically pre-scheduled and do not necessarily signal a change in insider sentiment.
• For retail investors, purchases generally carry more informational weight than routine sales; this report documents a routine disposition under a trading plan.